Physician profile
Eldred Wiser
NPI 1134192594
$1,439.90
in general payments reported to CMS, 2019-2025
26 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.99 · 2020: $185 · 2021: $192 · 2022: $318 · 2023: $240 · 2024: $266 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $453.10 | 2019-2024 | Liletta, Lo Loestrin Fe |
| Pfizer INC. | $122.30 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $102.28 | 2022-2024 | |
| Exeltis, USA INC. | $99.63 | 2023-2025 | Slynd |
| Avion Pharmaceuticals | $86.82 | 2019-2022 | |
| Hologic Sales and Service, LLC | $69.07 | 2020-2024 | Novasure, Myosure Tissue Removal Device |
| Bayer Healthcare Pharmaceuticals INC. | $62.22 | 2019-2025 | |
| Ethicon US, LLC | $44.60 | 2022-2024 | Ethicon |
| Meditrina | $39.65 | 2022-2023 | |
| Coopersurgical, INC. | $38.04 | 2022-2025 | Paragard T 380a |
| Agile Therapeutics, INC. | $34.00 | 2022 | |
| Sumitomo Pharma America, INC. | $32.00 | 2023 | Gemtesa, Myfembree |
| Evofem Biosciences, INC. | $30.21 | 2021 | |
| Daiichi Sankyo INC. | $23.74 | 2024 | Injectafer |
| Therapeuticsmd, INC. | $23.61 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $21.35 | 2022 | |
| Organon LLC | $21.34 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.89 | 2020 | |
| Smith+Nephew, INC. | $18.33 | 2024 | Pico 7 |
| Millicent US INC | $17.19 | 2024 | Femring, Intrarosa |
| Becton, Dickinson and Company | $16.92 | 2022 | |
| Astellas Pharma US INC | $16.09 | 2023 | Veozah |
| Sage Therapeutics, LLC | $15.37 | 2024 | |
| Minerva Surgical, INC | $11.74 | 2020 | |
| Coloplast Corp | $11.27 | 2020 | |
| Medela LLC | $9.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eldred Wiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.